501 results about "Nonalcoholic fatty liver disease" patented technology

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

The present disclosure relates to a system and method for non-invasively determining NAFLD activity scores (NAS) in patients using mechanical properties determined through magnetic resonance elastography (MRE) imaging. The non-invasively determined NAS score is then used to diagnose NFALD and NASH patients.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

The present invention relates to Spirocyclic Azetidinone Compounds, compositions comprising a Spirocyclic Azetidinone Compound and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of a Spirocyclic Azetidinone Compound.

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and / or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).

The invention discloses high-fat feed and application thereof in building an animal model with non-alcoholic fatty liver. The high-fat feed comprises the following raw materials in mass percent: 80.5% of rat breeding feed, 10% of egg, 7% of lard oil, 2% of cholesterol and 0.5% of No.3 bile salt. The model built in the invention can subsequently experience former three stages in the development ofthe clinical disease course of the non-alcoholic fatty liver: simple fatty liver, steato hepatitis and fibrosis. The model is used for studying the pathogenesis as well as the development mechanism of the non-alcoholic fatty liver, studying the prevention and treatment of the non-alcoholic fatty liver at different stages, and particularly for screening new medicines for preventing and treating fibrosis of the non-alcoholic fatty liver, screening measures for preventing and treating fibrosis of the non-alcoholic fatty liver and objectively evaluating the methods for preventing and treating thenon-alcoholic fatty liver at each stage.

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and / or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).

The present invention provides methods of identifying polypeptides that have enzymatic activity associated with nutrient and / or energy homeostasis, and thus, are involved in the development of one or more cardiovascular and metabolic disorders, e.g., cardiovascular disease, obesity, insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and metabolic syndrome. One such method comprises identifying a polypeptide as a member of the adiponutrin family of proteins. As such, the invention is related to the polynucleotides and polypeptides belonging to the adiponutrin family, and provides novel isolated and purified polynucleotides and polypeptides of a novel member of the adiponutrin family, patatin-like phospholipase domain 1 (PNPLA1). Also provided are methods of using the polynucleotides and polypeptides related to or provided by the invention for screening a test compound, e.g., a small molecule, antibody, etc., for the ability of the test compound to detect and / or modulate the activity of one or more members of the adiponutrin family of proteins. The present invention also is directed to novel methods for diagnosing, prognosing, and monitoring the progress of at least one cardiovascular and metabolic disorder using polynucleotides or polypeptides belonging to the adiponutrin family, and / or modulators of one or more members of the adiponutrin family. The present invention is further directed to novel therapeutics and therapeutic targets for the intervention (treatment) and prevention of cardiovascular and metabolic disorders arising from dysregulated energy homeostasis, as related to one or more members of the adiponutrin family of proteins.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

The invention discloses an ilicis routundae cortex medicinal composition for preventing and treating alcoholic liver damage, alcoholic fatty liver, non-alcoholic fatty liver and hyperlipidemia. The composition is extracted and refined from natural ilicis routundae cortex and is not chemically modified, and is characterized by comprising substances such as pedunculoside, syringin, rotundicacid and the like. The invention also discloses a preparation method of the ilicis routundae cortex composition and application to preparation of a medicament for preventing and treating the alcoholic liver damage, the alcoholic fatty liver and the non-alcoholic fatty liver and lowering blood fat.

The invention provides a method of detecting, monitoring, assessing and treating non-alcoholic fatty acid liver disease (NAFLD) and associated liver damage in a subject comprising measuring the amount of hepatocyte-derived circulating extracellular vesicles (EVs) and / or microparticle (MPs) in the bodily sample, or the expression level or activity of at least one biomarker expressed or detected in the EVs and / or MPs. The increased amount of EVs or MPs in the bodily sample and / or the increased expression or detection level of the biomarker of interest correlate with the degree or severity of NAFLD, NASH, liver fibrosis, or other associated liver damage, which can be associated with angiogenesis. Prevention and treatment of NAFLD, NASH, liver fibrosis or associated liver damage by reducing EVs or MPs, or targeting the biomarkers expressed in the EVs or MPs are also provided.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

The invention discloses a modeling method of a non-alcoholic fatty liver mouse model, and the method is characterized by consisting of the following steps that (1) a healthy mouse is caught and first adaptively raised for 3 to 7 days in an animal house, a backing material and clean water in a mouse cage are changed every day, and basic fodder is fed during that period of time; (2) after adaptive raising, composite high-fat fodder is fed every day; (3) 5 percent CC14 liquid is injected into the abdominal cavity of the mouse two weeks later, the liquid carbon tetrachloride is diluted to 5 percent emulsion with deionized water, and the liquid which is injected into the abdominal cavity shall be newly prepared; the abdominal cavity injection state continues for the 28th day, and meanwhile the composite high-fat fodder is fed; and the model is obtained. The modeling method has the advantages of short time, high modeling success rate, extremely low mortality rate and low cost.

The invention relates to preparation methods of sulphonylaminocarbonyl derivatives and compositions containing the same component and a use of the sulphonylaminocarbonyl derivatives as FXR and / or TGR5 agonists; the agonists are the sulphonylaminocarbonyl derivatives represented by the formula I, or pharmaceutically acceptable salts, prodrugs, solvates, hydrates, polymorphs, isomers, and stable isotope derivatives thereof. The compounds can be used for treatment of diseases and symptoms mediated by FXR and / or TGR5 and other therapeutic fields, wherein the diseases and symptoms include primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity.

The invention belongs to the field of biotechnology, and relates to a serum miRNA maker assemblage for detecting nonalcoholic fatty liver, and its application. The serum miRNA maker assemblage for detecting nonalcoholic fatty liver includes the following four has-microRNAs: hsa-miR-122-5p, hsa-miR-1290, hsa-miR-27b-3p and hsa-miR-192- 5p. The serum miRNA maker assemblage can realize early detection and rapid noninvasive detection of the nonalcoholic fatty liver.

The present invention provides a Chinese medicinal preparation with antihyperglycemic and cholagogic functions, which is prepared mainly from astragalus root, haw and rhubarb horsetails. The preparation also has the function of enlivening spleen, activating blood circulation and removing stasis.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum with a weight reducing function and an application of the lactobacillus fermentum. The lactobacillus fermentum is named as WHH3906, is separated from butter collected in Tibet Autonomous Region in China, is preserved in China General Microbiological Culture Collection Center on March 13, 2020, has a preservation number of CGMCC NO.19472, and is classified and named as lactobacillus fermentum. The lactobacillus fermentum strain can effectively reduce serum leptin level to recover leptin sensitivity of anorganism, effectively prevent and treat obesity, relieve non-alcoholic fatty liver and relieve chronic inflammation. After being compounded with lactobacillus plantarum 1701, the lactobacillus fermentum can synergistically relieve chronic inflammation.

Disclosed are: a marker for the diagnosis of a liver disease, which can determine the disease in a simple manner; an antibody directed against the marker; a diagnostic agent; a diagnosis method; and a method for marker detection in blood or serum. Proteome analysis revealed that quantities of the full-length kininogen and three partial peptides thereof (sequence A: position-440 to position-456, sequence B: position-439 to position-456, and sequence C: position-438 to position-456) in sera of patients with non-alcoholic fatty liver disease are significantly different from those in sera of healthy individuals; and a diagnostic agent and a detecting method for the non-alcoholic fatty liver disease that can be conveniently used for medical examination are established. The use of a combination of a kininogen-based marker and a C4-based marker (the full length sequence or partial peptides thereof) enables identification of chronic hepatitis and an asymptomatic virus carrier, as well as non-alcoholic fatty liver disease.

The invention discloses a traditional Chinese compound preparation for curing nonalcoholic fatty liver and central obesity and is characterized in that the compound preparation is prepared by adding medicinal excipient to the extractives of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris, wherein the weight mixture ratio of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris is 1-4:1:1-3:1-3:1-3. Proved by clinical trial, the drug combination of the invention can reduce the abdominal perimeter of patients, lower the AUC (area under curve) of triglyceride after dinner, improve the CT specific value of liver and spleen and bring down the transaminase level of liver with evident treatment effect. Verified by clinical research, the compound can obviously increase the insulin sensitivity of patients, lower inflammatory factor level and improve fibrinolysis-blood clotting function. Shown by experimental research, the drug of the invention can enhance the sensitivity of fat and muscle cells to insulin and has significant value in treating nonalcoholic fatty liver and central obesity which take insulin resistance as fundamental pathological link.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

The invention discloses a preparation method for a novel non-alcoholic fatty liver disease model. The preparation method comprises the following steps: a, randomly dividing fed mice into two groups, with one group being a model group and the other group being control mice, recording states everyday and taking urine, hepatic tissue and blood for lipid analysis; b, processing experimental subjects; c, building a model; d, collecting hepatic tissue and blood; e, preparing conventional frozen sections from hepatic tissue specimens of the mice, taking materials, wrapping the frozen sections with common glue and then successively carrying out dyeing and sealing; f, carrying out conventional pathological examination on model mice; g, carrying out conventional pathological examination on control mice; and h, comparing results of dynamic analysis of hepatic tissue fat obtained in step f and step g. The novel non-alcoholic fatty liver disease model established in the invention has the advantages of reasonable route, easy operation and strong pertinency and is an effective tool for further research on the non-alcoholic fatty liver disease.

The invention discloses application of adipose-derived mesenchymal stem cell exosomes in preparation of a medicine for treating metabolic syndrome. The adipose-derived mesenchymal stem cell exosomes are prepared through the following method: (1) dispersing a stripped adipose tissue into a digestion solution to produce cell suspension; (2) centrifugating the cell suspension to form cell sediments, and separating and washing the sediments, thus obtaining an adipose-derived mesenchymal stem cell-containing blood vessel matrix component; (3) performing multiplication culture on ADSC (adipose-derived stem cell) in an in-vitro culture system, collecting supernate obtained by the multiplication culture for concentration, and adding an exosome extraction reagent into the concentrated supernate, thus obtaining the adipose-derived mesenchymal stem cell exosomes through extracting. The adipose-derived mesenchymal stem cell exosomes can effectively relieve insulin resistance and metabolic disorders and inhibit occurrence and development of the metabolic syndrome and non-alcoholic fatty liver disease to a certain extent.

The invention belongs to the field of pharmaceuticals and relates to application of a cyclocarya paliurus effective part in preparation of health products and medicines which are used for treating a non-alcoholic fatty liver disease. The cyclocarya paliurus effective part mainly contains natural triterpenoid and can be used for effectively reducing rat liver lipid accumulation degree and triglyceride level which are caused by high fat diet, improving the liver histology and liver functions and improving the liver oxidative stress and the organism inflammatory level, so that the cyclocarya paliurus effective part can be used for obviously alleviating non-alcoholic fatty liver disease and preparing health products and medicines which are used for treating the non-alcohol fatty liver disease. The application of the cyclocarya paliurus effective part has the advantage that application range of cyclocarya paliurus preparation in the medical field.

The invention provides a hydroquinone farnesyl group compound and application of a pharmaceutical salt thereof in serving as an alpha-glucosidase, protein-tyrosine-phosphatase 1B or HMG-CoA reductase inhibitor, or in preparing drug for treating and / or preventing type-II diabetes or hyperlipidemia, or in preparing drug or functional healthcare products having hypoglycemic and hypolipidemic functions, or in preparing drug or functional healthcare products having a function of treating or preventing non-alcoholic fatty liver disease, or in preparing drug or functional healthcare products having liver protection effect, or in preparing drug or functional healthcare products for preventing and / or treating cancer or inhibiting tumor cell proliferation, or in serving as an RXRalpha receptor binding inhibitor, or in preparing drug serving as the RXRalpha receptor binding inhibitor. The inhibitors, the drug, food or the healthcare products prepared through the hydroquinone farnesyl group compound and the pharmaceutical salt are free of toxic and side effect and remarkable in treatment effect.

The invention provides a Chinese lizardtail rhizome or herb rootstock total effective fraction extract, which contains Chinese lizardtail rhizome or herb rootstock total lignan and total fatty acid and has the percentage by weight 10-90 percent. The invention further provides a preparation method and application of a Chinese lizardtail rhizome or herb rootstock total effective fraction. The Chinese lizardtail rhizome or herb rootstock total effective fraction extract can be used for preparing an insulin sensitizer medicinal preparation, has a good insulin sensitizing function, can be preparedinto various dosage forms such as oral tablets, capsules and the like, is suitable for treating insulin resistance-relevant diseases (such as type II diabetes, hypertension, obesity, nonalcoholic fatty liver and heart cerebrovascular thrombosis disease), and has the advantages of remarkable curative effect, low price, convenience for using, and the like.

The invention discloses purpose of naringenin, naringenin nanoliposome and a preparation method and application thereof. The naringenin is applied in the preparation of drugs for treating non-alcoholic fatty liver. The naringenin nanoliposome comprises naringenin and nanoliposome. The nanoliposome comprises phosphatide and cholesterol. The mass ratio of naringenin to phosphatide to cholesterol is 1:4-9:1-2. The preparation method comprises the following steps: 1) dissolving naringenin, phosphatide and cholesterol in a solvent, mixing, and removing the solvent to obtain a mixture; 2) hydrating the mixture obtained in the step 1) by the use of an aqueous medium to obtain a naringenin nanoliposome crude suspension; and 3) successively carrying out water-bath ultrasonic treatment and probe ultrasonic treatment on the naringenin nanoliposome crude suspension obtained in the step 2), so as to obtain the naringenin nanoliposome. The naringenin nanoliposome can raise oral bioavailability of naringenin and enhance the control effect of naringenin on non-alcoholic fatty liver.